The simultaneous occurrence of gestational diabetes and hypertensive disorders of pregnancy affects fetal growth and neonatal morbidity.

AGA GDM LGA SGA gestational hypertension neonatal morbidity

Journal

American journal of obstetrics and gynecology
ISSN: 1097-6868
Titre abrégé: Am J Obstet Gynecol
Pays: United States
ID NLM: 0370476

Informations de publication

Date de publication:
14 Mar 2024
Historique:
received: 15 08 2023
revised: 04 02 2024
accepted: 08 03 2024
medline: 17 3 2024
pubmed: 17 3 2024
entrez: 16 3 2024
Statut: aheadofprint

Résumé

Gestational diabetes (GDM) is associated with an increased risk of hypertensive disorders of pregnancy (HDP), but there are limited data on fetal growth and neonatal outcomes when both conditions are present. We evaluated the risk of abnormal fetal growth and neonatal morbidity in pregnancies with co-occurrence of GDM and HDP. In a retrospective study of 47,093 singleton pregnancies, we compared the incidence of appropriate for gestational age birthweight (AGA) in pregnancies affected by GDM alone, HDP alone, or both GDM and HDP (GDM/HDP) to that in pregnancies affected by neither disorder using generalized estimating equations (covariates: maternal age, nulliparity, BMI, insurance type, race, marital status and prenatal care site). Secondary outcomes were large for gestational age birthweight (LGA), small for gestational age birthweight (SGA), and a neonatal morbidity composite outcome (stillbirth, hypoglycemia, hyperbilirubinemia, respiratory distress, encephalopathy, preterm delivery, neonatal death, neonatal intensive care unit admission). The median [IQR] birthweight percentile in GDM/HDP (50 [24.0, 78.0], N=179) was similar to unaffected pregnancies (50 [27.0, 73.0], N=35,833). Yet, the absolute rate of AGA was lower for GDM/HDP (78.2% versus 84.9% for unaffected pregnancies). Adjusted analyses showed decreased odds of AGA in GDM/HDP pregnancies compared to unaffected pregnancies (aOR 0.72, 95% confidence interval [0.52, 1.00], P=0.049), and in pregnancies complicated by GDM alone (aOR 0.78 [0.68, 0.89], P<0.001), or HDP alone (aOR 0.73 [0.66, 0.81], P<0.001). The absolute risk of LGA in GDM/HDP pregnancies (14.5%) was greater than in unaffected pregnancies (8.2%) without apparent difference in the risk of SGA (7.3% vs 6.9%). However, in adjusted models comparing GDM/HDP to unaffected pregnancies, neither an association with LGA (aOR 1.33 [0.88, 2.00], P=0.171) nor SGA (aOR 1.32 [0.80, 2.19], P=0.293) reached statistical significance. GDM/HDP carried an increased risk of neonatal morbidity that was greater than that seen in either condition alone (GDM/HDP: aOR 3.13 [2.35, 4.17], P<0.001; GDM alone: aOR 2.01 [1.78, 2.27], P<0.001, HDP alone: aOR 1.38 [1.26, 1.50], P<0.001). While GDM/HDP pregnancies have a similar median birthweight percentile to those affected by neither condition, pregnancies concurrently affected by both conditions have a higher risk of abnormal fetal growth and neonatal morbidity.

Sections du résumé

BACKGROUND BACKGROUND
Gestational diabetes (GDM) is associated with an increased risk of hypertensive disorders of pregnancy (HDP), but there are limited data on fetal growth and neonatal outcomes when both conditions are present.
OBJECTIVES OBJECTIVE
We evaluated the risk of abnormal fetal growth and neonatal morbidity in pregnancies with co-occurrence of GDM and HDP.
STUDY DESIGN METHODS
In a retrospective study of 47,093 singleton pregnancies, we compared the incidence of appropriate for gestational age birthweight (AGA) in pregnancies affected by GDM alone, HDP alone, or both GDM and HDP (GDM/HDP) to that in pregnancies affected by neither disorder using generalized estimating equations (covariates: maternal age, nulliparity, BMI, insurance type, race, marital status and prenatal care site). Secondary outcomes were large for gestational age birthweight (LGA), small for gestational age birthweight (SGA), and a neonatal morbidity composite outcome (stillbirth, hypoglycemia, hyperbilirubinemia, respiratory distress, encephalopathy, preterm delivery, neonatal death, neonatal intensive care unit admission).
RESULTS RESULTS
The median [IQR] birthweight percentile in GDM/HDP (50 [24.0, 78.0], N=179) was similar to unaffected pregnancies (50 [27.0, 73.0], N=35,833). Yet, the absolute rate of AGA was lower for GDM/HDP (78.2% versus 84.9% for unaffected pregnancies). Adjusted analyses showed decreased odds of AGA in GDM/HDP pregnancies compared to unaffected pregnancies (aOR 0.72, 95% confidence interval [0.52, 1.00], P=0.049), and in pregnancies complicated by GDM alone (aOR 0.78 [0.68, 0.89], P<0.001), or HDP alone (aOR 0.73 [0.66, 0.81], P<0.001). The absolute risk of LGA in GDM/HDP pregnancies (14.5%) was greater than in unaffected pregnancies (8.2%) without apparent difference in the risk of SGA (7.3% vs 6.9%). However, in adjusted models comparing GDM/HDP to unaffected pregnancies, neither an association with LGA (aOR 1.33 [0.88, 2.00], P=0.171) nor SGA (aOR 1.32 [0.80, 2.19], P=0.293) reached statistical significance. GDM/HDP carried an increased risk of neonatal morbidity that was greater than that seen in either condition alone (GDM/HDP: aOR 3.13 [2.35, 4.17], P<0.001; GDM alone: aOR 2.01 [1.78, 2.27], P<0.001, HDP alone: aOR 1.38 [1.26, 1.50], P<0.001).
CONCLUSIONS CONCLUSIONS
While GDM/HDP pregnancies have a similar median birthweight percentile to those affected by neither condition, pregnancies concurrently affected by both conditions have a higher risk of abnormal fetal growth and neonatal morbidity.

Identifiants

pubmed: 38492713
pii: S0002-9378(24)00438-1
doi: 10.1016/j.ajog.2024.03.009
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Auteurs

Chioma Onuoha (C)

School of Medicine, University of California, San Francisco, San Francisco, CA.

Carolin C M Schulte (CCM)

Biostatistics Center, Massachusetts General Hospital, Boston MA.

Tanayott Thaweethai (T)

Biostatistics Center, Massachusetts General Hospital, Boston MA; Harvard Medical School, Boston, Massachusetts.

Sarah Hsu (S)

Broad Institute, Cambridge, Massachusetts; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, 100 Cambridge, Boston, MA, USA.

Deepti Pant (D)

Biostatistics Center, Massachusetts General Hospital, Boston MA.

Kaitlyn E James (KE)

Harvard Medical School, Boston, Massachusetts; Department of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Sarbattama Sen (S)

Harvard Medical School, Boston, Massachusetts; Department of Pediatrics, Brigham and Women's Hospital.

Anjali Kaimal (A)

University of South Florida Morsani College of Medicine, Department of Obstetrics and Gynecology, 2 Tampa General Circle, Tampa, FL 33606.

Camille E Powe (CE)

Harvard Medical School, Boston, Massachusetts; Broad Institute, Cambridge, Massachusetts; Diabetes Unit, Endocrine Division, Massachusetts General Hospital, Boston, MA. Electronic address: camille.powe@mgh.harvard.edu.

Classifications MeSH